Emergent veno-arterial extra-corporeal membrane oxygenator support for refractory acute myocarditis in paediatric

Mimoza Maldi1, Guido M Olivieri2, Simone Ghiselli1

  • 1Congenital Cardiac Surgery De Gasperis Cardio Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Cardiology in the Young
|September 27, 2024
PubMed

Insights

Severe heart failure in children due to acute myocarditis is rare but serious. Veno-arterial extra-corporeal membrane oxygenation (VA-ECMO) is critical for survival in cardiogenic shock, and this study examines VA-ECMO outcomes.

Area of Science:

  • Pediatric Cardiology
  • Cardiovascular Surgery
  • Critical Care Medicine

Background:

  • Acute myocarditis can cause severe heart failure in children.
  • Refractory cardiogenic shock necessitates mechanical circulatory support.
  • Veno-arterial extra-corporeal membrane oxygenation (VA-ECMO) is a key intervention.

Purpose of the Study:

  • To evaluate short- and long-term patient outcomes.
  • To analyze the effectiveness of VA-ECMO in pediatric acute myocarditis.
  • To provide data on survival and recovery post-VA-ECMO.

Main Methods:

  • Retrospective analysis of pediatric patients with acute myocarditis.
  • Inclusion of patients requiring VA-ECMO for cardiogenic shock.
  • Assessment of in-hospital, short-term, and long-term outcomes.

Main Results:

  • In-hospital mortality for VA-ECMO support is approximately 30%.
  • VA-ECMO effectively restores perfusion in pediatric cardiogenic shock.
  • Further analysis of short- and long-term outcomes is presented.

Conclusions:

  • VA-ECMO is a vital treatment for pediatric acute myocarditis with refractory cardiogenic shock.
  • Understanding VA-ECMO outcomes is crucial for patient management.
  • This study contributes to the knowledge of VA-ECMO's role in pediatric critical care.

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
2
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
124
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
2